BASF Pharma Solutions

Belkins
BASF creates chemistry for a sustainable future offering intelligent solutions to the pharmaceutical industry. With its expertise in polymer chemistry, R&D-capabilities and its commitment in developing excipients, BASF creates solutions for Instant & Modified Release, Solubilization, Softgels, Skin-Delivery and Biologics. BASF is the leading supplier of selected APIs such as ibuprofen and omega-3.

Related News

BUSINESS INSIGHTS

HIKMA AND FAES FARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR THE COMMERCIALISATION OF BILASTINE TABLETS IN THE US

Hikma Pharmaceuticals PLC | September 21, 2021

news image

Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, announces the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria. Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercial...

Read More

VIEWS AND ANALYSIS

CMIC AND LOKAVANT COLLABORATE TO DEPLOY MACHINE LEARNING-POWERED CLINICAL TRIAL INTELLIGENCE PLATFORM

CMIC | June 25, 2021

news image

CMIC Co., Ltd., a leading Japanese Contract Research Organization (CRO), and Lokavant, a leading clinical trial intelligence company, announced today that they have agreed to use Lokavant's predictive analytics capabilities to assist CMIC's clinical operations. This strategic collaboration, Lokavant Oversight, monitoring, and operational risk management platform, will be implemented throughout CMIC studies. CMIC was the first firm in Japan to provide CRO services, and the ...

Read More

OSTRICH PHARMA USA PRODUCES ANTIBODIES TO BLOCK THE VIRUS THAT CAUSES COVID-19

Business Wire: | April 01, 2020

news image

Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S. Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs. These antibodie...

Read More

BUSINESS INSIGHTS

NAMSA ACQUIRES LEADING CLINICAL RESEARCH ORGANIZATION CLINLOGIX TO ENHANCE THERAPEUTIC EXPERTISE AND GLOBAL FOOTPRINT

NAMSA | August 03, 2021

news image

NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of Clinlogix, a leading, Philadelphia-based global clinical research organization. Third in an advancing series, this acquisition follows NAMSA’s purchase announcements of Syntactx and American Preclinical Services (APS) in early 2021. Clinlogix, founded in 1999, is well-recognized for providing compreh...

Read More
news image

BUSINESS INSIGHTS

HIKMA AND FAES FARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR THE COMMERCIALISATION OF BILASTINE TABLETS IN THE US

Hikma Pharmaceuticals PLC | September 21, 2021

Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, announces the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria. Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercial...

Read More
news image

VIEWS AND ANALYSIS

CMIC AND LOKAVANT COLLABORATE TO DEPLOY MACHINE LEARNING-POWERED CLINICAL TRIAL INTELLIGENCE PLATFORM

CMIC | June 25, 2021

CMIC Co., Ltd., a leading Japanese Contract Research Organization (CRO), and Lokavant, a leading clinical trial intelligence company, announced today that they have agreed to use Lokavant's predictive analytics capabilities to assist CMIC's clinical operations. This strategic collaboration, Lokavant Oversight, monitoring, and operational risk management platform, will be implemented throughout CMIC studies. CMIC was the first firm in Japan to provide CRO services, and the ...

Read More
news image

OSTRICH PHARMA USA PRODUCES ANTIBODIES TO BLOCK THE VIRUS THAT CAUSES COVID-19

Business Wire: | April 01, 2020

Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S. Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs. These antibodie...

Read More
news image

BUSINESS INSIGHTS

NAMSA ACQUIRES LEADING CLINICAL RESEARCH ORGANIZATION CLINLOGIX TO ENHANCE THERAPEUTIC EXPERTISE AND GLOBAL FOOTPRINT

NAMSA | August 03, 2021

NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of Clinlogix, a leading, Philadelphia-based global clinical research organization. Third in an advancing series, this acquisition follows NAMSA’s purchase announcements of Syntactx and American Preclinical Services (APS) in early 2021. Clinlogix, founded in 1999, is well-recognized for providing compreh...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us